Sydney

Beroni Group Received a US$1.07 Million Order for COVID-19 Antigen Test Kits from Japan

Retrieved on: 
Thursday, November 18, 2021
Trial of the century, Perception, CEO, Sale, School, Consultant, Industry, CE, Forward-looking statement, Company, Population, Cancer, BTG, COVID-19, Nature, OTCQX, Death, Research, Tax, GLOBE, National Stock Exchange of Australia, Marketing, Terminology, OTC, Infection, National Stock Exchange, NSX, Certification, Failure, Pharmaceutical industry, Vaccine

Beroni has so far produced and delivered about two thirds of the test kits to the buyer.

Key Points: 
  • Beroni has so far produced and delivered about two thirds of the test kits to the buyer.
  • The SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) optimizes the sample collection process.
  • This greatly improves the convenience of testing and the test results can be obtained within 10 minutes.
  • The antigen test kit was prepared using colloidal gold solid-phase immunochromatography and is used for qualitative assays of SARS-CoV-2 antigen samples in vitro.

SyncDAO teams up with MANTRA DAO to use ZENDIT Launchpad for IDO

Retrieved on: 
Thursday, November 18, 2021
Partnership, HECO, Goal, MANTRA, Decentralized finance, PVT, GLOBE, DAO, Polka dot, Cryptocurrency

Working with a team that is focused on improving the whole space was super important to us, thats why we chose to work with MANTRA DAO.

Key Points: 
  • Working with a team that is focused on improving the whole space was super important to us, thats why we chose to work with MANTRA DAO.
  • The combination of SyncDAOs Perpetual Vaults and their affiliate smart contract layer is a killer product MANTRA DAO Co-Founder John Patrick Mullin.
  • The partnership with MANTRA DAO is just one of several that the SyncDAO team is announcing ahead of its official launch.
  • MANTRA DAO has built a suite of DeFi services including a multi-asset staking platform, money markets lending protocol, gamified lottery pool, and token issuance launchpad.

Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha

Retrieved on: 
Monday, November 15, 2021
MSD, Safety, Neck, Maintenance, Cancer, PD-L1, LAG-3, AIPAC, Merck, NASDAQ, APC, Technology, TPS, Infection, Autoimmune disease, Pembrolizumab, Calendar, Endpoint security, Australian Securities Exchange, Immutep, Patient, IMP321, IMM, Large-cell lung carcinoma, Antibody, Merck Sharp & Dohme Federal Credit Union, NSCLC, ORR, Webcast, Paclitaxel, CPS, PFS, Head, OS, Merck & Co., RECIST, Pharmaceutical industry, Medical device, Medical imaging, Dietary supplement, Palladium, Vaccine

TACTI-003 is a Phase IIb multicentre, open label, randomised and controlled, trial enrolling approximately 154 patients with 1st line HNSCC.

Key Points: 
  • TACTI-003 is a Phase IIb multicentre, open label, randomised and controlled, trial enrolling approximately 154 patients with 1st line HNSCC.
  • The primary endpoint of the study is ORR according to RECIST 1.1. and iRECIST will be used for treatment decisions.
  • Active Immunotherapy Paclitaxel (AIPAC) is a multicentre, placebo-controlled, double-blind, 1:1 randomisedPhase IIb clinical trial in HER2-negative/HR positive metastatic breast cancer.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD-1 Pathway Inhibitor

Retrieved on: 
Monday, November 15, 2021
NASDAQ, APC, EOC, Technology, Infection, Autoimmune disease, Investment, Treatment, Immunotherapy, Research, Chinese patent medicine, Australian Securities Exchange, Greater, Immutep, IMM, Company, GLOBE, IMP321, Antibody, ASX, Patent, Patient, LAG-3, Pharmaceutical industry, Vaccine, Fine chemical

This new Chinese patent follows the grant of the corresponding European and United States patents announced in 2018 through 2021.

Key Points: 
  • This new Chinese patent follows the grant of the corresponding European and United States patents announced in 2018 through 2021.
  • The claims are also directed to use of the preparations for the manufacture of a medicament for the treatment of cancer and infectious disease.
  • Immutep CEO, Marc Voigt, noted: This new patent again highlights the important investments Immutep is making to protect efti, with its unique mode of action.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Transhuman Coin Listed on CoinMarketCap and CoinGecko: Leads the Token to New All-Time High

Retrieved on: 
Monday, November 15, 2021
Intelligence, Transhuman, Science, Student, Health, Biotechnology, Longevity, Disease, Technology, Disability, Research, Sale, Life extension, Marketing, Solution, Blockchain, Death, Conditional sentence, Biology, Life, Cryptocurrency, Renewable energy

It is a research and charity-oriented cryptocurrency, which is announced by Transhuman co-founders Dr. Charles Awuzie and Peter Xing.

Key Points: 
  • It is a research and charity-oriented cryptocurrency, which is announced by Transhuman co-founders Dr. Charles Awuzie and Peter Xing.
  • Figure 1: Transhuman Coin listed on CoinMarketCap and CoinGecko: leads the token to New All-Time High
    Founded with an ideology of improving human life through science and technology, the project is one of the first in the market to merge Biotechnology with Blockchain Technology.
  • As a research and charity oriented token, a portion of each transaction is earmarked to fund science and technology initiatives.
  • "The Transhuman Fund portfolio is dedicated to this project," remarked Peter Xing, co-founder of Transhuman Coin.

Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details

Retrieved on: 
Tuesday, November 9, 2021
SITC, Cancer, PD-L1, HNSCC, NASDAQ, EST, Autoimmune disease, Immunotherapy, 2021 Essex County Council election, MBC, IMM, GLOBE, ORR, ASX, Paclitaxel, Patient, LAG-3, Total, Pharmaceutical industry

Data from Phase IIb AIPAC, including final Overall Survival data, reported in a separate announcement

Key Points: 
  • Data from Phase IIb AIPAC, including final Overall Survival data, reported in a separate announcement
    Total of 154 1st line HNSCC patients, unselected for PD-L1 expression, will be recruited into Phase II TACTI-003 study to determine ORR as primary endpoint
    SYDNEY, AUSTRALIA, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that data from its AIPAC, TACTI-002 and TACTI-003 studies have been published in abstracts available via the links below on the SITC 2021 Annual Meetings official website or the Companys website.
  • Three poster presentations with additional data and commentary that are not included in the abstracts will be available on https://www.sitcancer.org/2021/home from 12 November 2021, at 7 am EST and made available on Immuteps website at www.immutep.com .
  • Note: A separate announcement detailing the AIPAC results has also been released today.
  • Title: Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC.

Immutep Reports Improved and Statistically Significant Survival Benefit for Three Key Patient Groups in Final Phase IIb AIPAC Study Results in Metastatic Breast Cancer

Retrieved on: 
Tuesday, November 9, 2021
Population, SITC, Cancer, III, CMO, Monocyte, AIPAC, NASDAQ, APC, Immune system, Survival, Autoimmune disease, Society, AEDT, Immunotherapy, MBC, Society for Immunotherapy of Cancer, Immutep, Patient, IMM, GLOBE, Luminal, HR, UZ Leuven, Paclitaxel, ASX, CD8, OS, CDK, Pharmaceutical industry, Health insurance, Vaccine

227 patients with HER2-negative/HR positive metastatic breast cancer (HR+ MBC) were 1:1 randomisedin the placebo-controlled, double-blind AIPAC study.

Key Points: 
  • 227 patients with HER2-negative/HR positive metastatic breast cancer (HR+ MBC) were 1:1 randomisedin the placebo-controlled, double-blind AIPAC study.
  • The results from our AIPAC trial are especially pleasing because metastatic breast cancer patients in the chemotherapy setting are a difficult to treat and large patient population where immunotherapies often fail to provide an additional benefit.
  • These supportive results are also timely as we solidify the trial design for our planned Phase III study in metastatic breast cancer, subject to regulatory body interactions.
  • Immutep CSO and CMO, Frederic Triebel, noted: The final results from our Phase IIb AIPAC trial represent the most definitive insights we have reported relating to the clinical benefit efti has on overall survival for metastatic breast cancer patients.

Recce Pharmaceuticals to Give Opening R&D Address at World Anti-Microbial Resistance Congress 2021

Retrieved on: 
Monday, November 8, 2021
Therapeutic Products Directorate, Synthetic, GAIN, FSE, Congress, AMR, Degenerative disease, Sepsis, Bacteria, Company, GLOBE, Virus, Hope, RCE, ASX, Pew, Recce, FDA, Gram-negative bacteria, Pharmaceutical industry, Vaccine, Antibiotics

SYDNEY, Australia, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (Company), the Company developing new classes of synthetic anti-infectives, today announced it will be delivering the Opening R&D Address at the World Anti-Microbial Resistance (AMR) Congress being held November 8th-9th, 2021.

Key Points: 
  • SYDNEY, Australia, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (Company), the Company developing new classes of synthetic anti-infectives, today announced it will be delivering the Opening R&D Address at the World Anti-Microbial Resistance (AMR) Congress being held November 8th-9th, 2021.
  • Recce Chairman, John Prendergast, Ph.D., will deliver the 20-minute Opening R&D Address, highlighting the urgent need for new antibiotics to address the rapidly growing threat of AMR.
  • The two-day World AMR Congress held in Washington DC is the largest AMR conference in the world with more than 1,000 attendees from over 50 countries.
  • The World AMR Congress continues to be the go-to platform for leading antibiotic developers, such as Recce Pharmaceuticals, to connect with global AMR stakeholders and further initiatives aimed at combatting antimicrobial resistance.

Introducing Skylight Exchange (SLT) Token, a 3-in-1 Exchange Token Combining DEFi Exchange, NFT Market Place and E-Commerce Shop

Retrieved on: 
Friday, November 5, 2021
Crypto, Ethereum, Ecosystem, Decentralized exchange, Cryptocurrency, Decentralized finance, DEX, AMM, Sale, BSC, Blockchain, NFT, Non-fungible token, SLT

SLT token will be the native currency of the Skylight exchange and online store.

Key Points: 
  • SLT token will be the native currency of the Skylight exchange and online store.
  • Figure 1: Skylight Exchange (SLT) Token a 3-in-1 exchange Token combining DEFi Exchange, NFT Market Place and E-Commerce Shop
    To view an enhanced version of this graphic, please visit:
    Skylight token is an exchange token built on three blockchain networks (BSC, Ethereum and Polygon).
  • Additionally, Skylight Exchange will also support the creation, sale and purchase of NFT digital art and Collectibles on a secured blockchain.
  • Skylight exchange as a DeFi exchange will allow users to perform trading and yield farming and staking of other cryptocurrencies on the exchange to earn rewards.

Nanocelle® Patent Granted in Usa

Retrieved on: 
Thursday, November 4, 2021
Safety, Head, Gender representation on corporate boards of directors, Compliance, United States patent law, ASX, CEO, Board, MDC, Pharmaceutical industry

SYDNEY, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Medlab Clinical Ltd (ASX: MDC) is extremely pleased to announce the USPTO has granted patent protection for NanoCelle® “Transmucosal and transdermal delivery systems” (Patent No. 11160753) in the United States of America. This announcement follows just three weeks after announcing the ‘Notice of Allowance’ received by the USPTO. (October 06, 2021).

Key Points: 
  • The granting of NanoCelle US Patent gives Medlab the Green-light to pursue potential partnering opportunities in the largest and most powerful marketplace in the world.
  • NanoCelle, the patented delivery platform is wholly owned by Medlab and developed in Medlabs owned OGTR Registered Laboratory.
  • NanoCelle is designed to address known medication problems, addressing global unmet medical needs.
  • Medlab operates in Australia (Head Office), USA, and the UK.